Type of medicine: Centrally authorised medicines
|
Therapeutic area: Endocrine System Diseases
|
Brands: Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report |
MAH holders: Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report, Please see report |
Assessment: |
Active substance: insulin detemir |
ATC code: A10AE05 |
Document link:
NN304-1633-synopsis.pdf
|
Document date: 2011-09-23
|
Study number: NN304-1633 |
EudraCT number:
|
Scope of study: CLINICAL |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
Y
|